Ironwood Pharmaceuticals Inc Dossier - Source-backed chat

Ironwood Pharmaceuticals Inc

IRWDNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.50

Intrinsic Value $7.82median of 3 methodsbased on filings through 30 Jun 2026

Market Price $3.76Price as of 1 Oct 2026

Significantly undervaluedIntrinsic value is 108% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+108%)

Data confidence Sign in to view data confidence

Market Cap $621.3M

Enterprise Value $741.7M

Shares Outstanding 168.7M diluted

Next Earnings Date29 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Ironwood Pharmaceuticals presents a compelling contrarian buy opportunity. Despite recent short-term stock pressure driven by the resignation of CFO Gregory Martini and insider selling, the company's underlying fundamentals remain exceptionally strong. Ironwood's core asset, LINZESS, continues to demonstrate robust commercial performance, highlighted by a 97% year-over-year increase in U.S. net sales in Q1 2026. This growth is supported by improved net pricing and the elimination of inflationary rebates. Furthermore, the company is well-positioned to advance its next-generation GLP-2 analog, apraglutide, through the Phase III STARS-2 trial, which holds significant blockbuster potential in short bowel syndrome. Trading at a highly compressed forward multiple, the stock significantly undervalues Ironwood's cash-generation capabilities and pipeline optionality.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.70

Mean target$6.35

High · most bullish analyst$11.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$3.7015%

LINZESS faces unexpected pricing pressure or market share erosion from competitive treatments, causing full-year revenues to fall short of guidance. The STARS-2 trial encounters clinical or enrollment delays, pushing back the timeline for apraglutide's development. Prolonged leadership vacancy or further executive turnover continues to weigh on investor confidence, keeping the valuation multiples compressed.

Base CaseCentral scenario

$6.9060%

LINZESS maintains its market leadership in IBS-C and CIC, delivering low single-digit prescription demand growth and meeting the full-year U.S. net sales guidance of $1.125B to $1.175B. The STARS-2 Phase III trial for apraglutide initiates sites successfully in mid-2026 and proceeds on track. The company successfully repays its June 2026 convertible notes in cash, and a seamless CFO transition stabilizes investor sentiment, leading to a steady re-rating of the stock.

Bull CaseUpside scenario

$10.0025%

LINZESS experiences accelerated demand growth driven by the newly approved pediatric indication for functional constipation in children aged 2 to 5 years. Apraglutide's STARS-2 Phase III trial progresses ahead of schedule, demonstrating best-in-class efficacy and safety, which positions it for rapid regulatory approval and a highly successful commercial launch. Strong cash flows allow the company to comfortably service its debt while aggressively pursuing further pipeline expansion.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong commercial performance of LINZESS, which achieved 97% YoY U.S. net sales growth in Q1 2026 due to improved net pricing.
Robust cash generation, with $220.5 million in cash and cash equivalents as of March 31, 2026, supporting the cash repayment of the June 2026 convertible notes.
High-potential pipeline asset in apraglutide, a next-generation GLP-2 analog targeting short bowel syndrome with intestinal failure (SBS-IF).
Expanded market opportunity for LINZESS following the FDA approval for pediatric functional constipation (ages 2 to 5) in late May 2026.

Key Investment Risks

Near-term leadership uncertainty following the resignation of CFO Gregory Martini in May 2026.
Revenue lumpiness due to the profit-sharing structure with AbbVie, which can lead to quarterly volatility and investor concern.
Clinical development and regulatory risks associated with the Phase III STARS-2 trial for apraglutide.

Thesis Invalidation Triggers

Failure to successfully initiate or enroll patients in the STARS-2 Phase III trial for apraglutide.
A material downward revision of the full-year 2026 financial guidance for LINZESS sales or adjusted EBITDA.
Inability to secure a qualified permanent CFO within a reasonable timeframe, leading to prolonged corporate governance concerns.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.